Login

Terns Pharmaceuticals, Inc. SEC Filings

Filed On Filing
05 Jun 2026 SCHEDULE 13G/A
15 May 2026 15-12G
13 May 2026 SCHEDULE 13G/A
12 May 2026 SCHEDULE 13G/A
07 May 2026 EFFECT
05 May 2026 Form 4: Azelby Robert, Director

Disposed of 91,697 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Turner Heather D, Director

Disposed of 110,697 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Tripuraneni Radhika, Director

Disposed of 190,030 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Quigley Jill M., Director

Disposed of 147,309 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Kindler Jeffrey B, Director

Disposed of 208,505 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Fellows David A, Director

Disposed of 221,136 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Kuriakose Emil, Chief Medical Officer

Disposed of 24,562 shares (Tender Offer) ($1.3M) · Returned 81,953 shares to the issuer ($4.34M) · Disposed of 1,115,000 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Gengos Andrew, Chief Financial Officer

Disposed of 40,503 shares (Tender Offer) ($2.15M) · Returned 68,750 shares to the issuer ($3.64M) · Disposed of 887,500 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 Form 4: Burroughs Amy L., Director

Disposed of 154,933 shares (Tender Offer) ($8.21M) · Returned 150,000 shares to the issuer ($7.95M) · Disposed of 2,505,534 Stock Option (Right to Buy) (Disposition to Issuer)

05 May 2026 S-8 POS
05 May 2026 S-8 POS
05 May 2026 S-8 POS
05 May 2026 S-8 POS
05 May 2026 S-8 POS
05 May 2026 S-8 POS

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support